Irritable Bowel Synrome (IBS) is a functional bowel disorder characterized by chronic abdominal pain, abdominal discomfort, abdominal distension (swelling) and changes in bowel habits in the absence of an organic disease.
Irritable Bowel Syndrome is successfully treated. The key to a successful treatment lies in the causes.
Cellular & Molecular Therapeutic Treatment
- Patients do not change eating habits, nor their lifestyle
- Without taking chemical and pharmaceutical substances
- Treatments act individually or combined without side effects
- Permanent solution to the problem
In some cases the symptoms persist after gut-purging. It may occur in the form of diarrhea or constipation, or by alternation of these (classified as IBS-D, IBS-C or IBS-A respectively). Also, the ΙΒS can occur after an infection (post-infectious, IBS-PI) or a stressful condition.
Various conditions can be experienced as the ACE, such as celiac disease (gluten malabsorption), fructose malabsorption, infections, parasitic infections such as gallbladder, idiopathic inflammatory bowel disease, chronic functional constipation and chronic functional abdominal pain.
Symptoms involve many people as it appears that 10-20% of the world population is suffering from IBS, with new incidents per year accounting to 1-2%. Of those who suffer from IBS, only 10-20% seek medical help, while 20-50% of visits involve irritable bowel syndrome.
Women seem to have a chance to develop IBS 2-3 times more than men. In studies conducted that divided the population based on age, a decrease was observed in the elderly. Available data show that irritable bowel syndrome is rare in sub-Saharan Africa, but common in China, India and South America.
Symptoms of Irritable Bowel Syndrome
Symptoms of Irritable Bowel Syndrome are:
- Disorder in bowel habits (diet – constipation – alternations),
- Abdominal pain,
- Flatulence (bloating).
It may also be accompanied by:
- Mucus in the stools,
- Indigestion, burning, nausea, vomiting,
- Increased frequency of Urination αυξημένη συχνότητα ούρησης,
- Aggravation of symptoms during menstruation,
- Muscle Pain
The fact that the irritable bowel is mainly a female syndrome (2: 1 ratio), suggests that sex hormones play a key role in causing the symptoms.
During menstruation, female hormones that cause mobility disturbances and gastrointestinal symptoms, change due to the presence of hormone receptors in the gastrointestinal wall. The hormone responsible mainly for gastrointestinal symptoms is progesterone which increases during menstruation.
In particular, we have a decrease in estrogen levels and an increase in the levels of progesterone in the luteal phase which cause an increase in the expression of the serotonin receptor in the intestine leading to a worsening of the symptoms of the intestine (increased mobility) and visceral pain hypersensitivity.
Irritable Bowel Syndrome & Stress Hormones
The list of hormones that have an effect on gastrointestinal function does not stop there. Adrenal hormone, cortisol is one that is particularly high in women with irritable bowel syndrome, which confirms that stress affects the progression of the disease.
Another hormone confirming this conclusion is corticotropin. This hormone is responsible for sending a signal to the intestine in order to shed large amounts of water and mucus by accelerating the defecation process. But because the stimulus does not stop after defecation, that’s why we feel like we want to go back to the toilet.
Food Intolerance Τροφική & Irritable Bowel Syndrome
Many patients with irritable bowel syndrome believe that the symptoms of the disease are triggered by specific foods, but this causal relationship is difficult to prove. Milk, wheat and eggs, as well as foods rich in salicylate (coffee, nuts, corn, wine, tomato, etc.) or amines (chocolate, banana, wine, etc.) are the foods most responsible for the exacerbation of symptoms.
The role of malabsorption of individual sugars (ie lactose, fructose and sorbitol) in the development of symptoms of irritable bowel syndrome deserves particular reference. Lactose malabsorption has been reported to occur in 25% of patients with irritable bowel syndrome in the United States and in northern Europe, while the prevalence in the Mediterranean countries may reach 52-68%. The malabsorption of lactose can cause diarrhea and flatulence and thus occurs more frequently in the subgroup of patients who are overwhelmed with these symptoms.
Malabsorption of fructose and sorbitol also occurs in patients with irritable bowel syndrome. The prevalence of malabsorption is particularly high when these two sugars are administered simultaneously (31-92%). Although these percentages are not different from those measured in healthy control individuals, the intensity of the symptoms after glucose uptake is significantly greater in patients with irritable bowel syndrome. This difference does not appear to be due to intestinal dyskinesia and the hypersensitivity to dilatation, but to the increase in fermentation capacity to patients with irritable bowel syndrome.
Examinations for diagnosing individuals with Irritable Bowel Syndrome
Investigation of young patients with typical irritable bowel syndrome without signs of “alarm” for organic digestive disease does not require laboratory testing.
In patients with multiple diarrheal stools, the function of the thyroid gland should be tested and biopsies should be taken from the intestine to exclude microscopic or eosinophilic colitis. In the case of suspected bacterial overgrowth, the exhaled hydrogen test is useful.
If laboratory testing is required, the choice should be personalized based on their symptoms, their severity and the patient’s concerns. For patients with a short duration of symptoms, relatively young (but less than 50 years of age) and no obvious effusions for irritable bowel syndrome, general blood test, erythrocyte sedimentation rate (ESR) and colorectal examination can be used as initial screening tests.
The use of other tests such as CRP, biochemical tests, general microscopic and faecal parasitology are also some tests deemed necessary depending on the patient’s symptomatology and medical history.
We need to be careful and be checked when the onset of symptomatology starts after the middle age, and it is sudden. Also, when it is progressively worsening, when it causes night-time awakening and in cases where it is accompanied by anorexia, weight loss, fever and loss of blood in the stools. We also need to be careful when diarrhea is not painful but also when there are suspicions of malabsorption. Still, if there is a medical diagnosis of IBS, any new symptom should lead to our doctor.
Usually, the treatment focuses on limiting symptomatology and psychological support is used, as well as dietary measures and medication. There are several medications that help relieve the symptoms of IBS. Commonly, spasmolytics (eg pinaverium / dicetel) are used, but others are also used, such as anticholinergics (eg hyoscyamine / buscopan), antidiarrheals (eg loperamide / Imodium), tricyclic antidepressants (eg amitriptyline (Eg, diazepam / Valium), prokinetics (eg metoclopramide / Primperan), laxatives increasing the amount of stools (eg paraffin liquid / Nujol), serotonin receptor antagonists Paroxetine / Seroxat), receptor agonists (e.g., tegaserod / Zelnorm), rifaximin (e.g., Lormyx).
Nonetheless, these specific treatments, although widely used for years, aim primarily at reducing the symptoms of the disease rather than finding its cause and actually dealing with irritable bowel syndrome.
Thus, patients suffer from repeated relapses and recurrence of symptoms, which also affects them psychologically.
Regarding to dietary management of the disease, it is recommended to drink an adequate amount of water (2-3 liters a day), avoid caffeine, reduce over-excitement and the exacerbate of symptoms. It is also good to avoid legumes because they cause “bloating”.
Lactose, fructose or other saccharides should be restricted or avoided in patients with known sensitivity. There are preparations in pharmacies that are not drugs and help. Flax fiber preparations, which are recommended for both constipation and diarrhea, are of great importance. There are also formulations of probiotics and prebiotics. Probiotics are living microorganisms similar to those of the gut and help balance the intestinal flora. Prebiotics are substances that help develop and maintain the existing intestinal flora. Studies on the IBS typically involve probiotics. It appears that probiotics modify the intestinal flora and affect its interaction with food components and the immune system, while improving general symptomatology and especially flatulence.
Given that IBS patients are a group that have multiple combinations of symptomatology and that microbial flora has excellent human to human variability, setting criteria for choosing the right probiotic formulation is difficult. Here, a pharmacist plays a very important role, who in close and frequent relationship with the patient can help identify the most effective probiotic.
Cellular, Molecular Therapeutic Treatment
However, because there are many conditions that affect our hormone levels, it is necessary to look at cell biochemistry through specific biochemical, hormonal and metabolic examinations, as these fluctuations affect the onset and exacerbation of irritable bowel symptoms. Therefore balancing the imbalances is necessary for the recession or even the complete disappearance of the symptoms.
With personalized medical treatments and protocols, we can intervene and personalize each type of deficiency and remove the toxic load.
With this methodology, we are basically restoring Health in a cellular level and restore the body’s ability to produce high-quality combustion necessary for Life.
The Medical Protocols that are administered adjust the amounts, doses and type of components that change from person to person (actual personalization), as opposed to 50,100 or 500mg identical dosing approaches for all.
The clinical results of the use of such Medical Protocols over the last 20 years are more than satisfactory, with rates of improvement and re-regulation of the body of over 80%. Patients undergoing treatment for Functional Medicine see the quality of their daily routine change. Their quality of life is improving. Along with treatment, their mental and physical resources are increasing.
Dr. Nikoleta Koini, M.D.
Doctor of Functional, Preventive, Anti-ageing and Restorative Medicine
Diplomate and Board Certified in Anti-aging, Preventive, Functional and Regenerative Medicine from A4M (American Academy in Antiaging Medicine).
- Nobuyuki Amino 4 Autoimmunity and hypothyroidism Bailiére’s Clinical Endocrinology and Metabolism Volume 2, Issue 3 August 1988. doi:10.1016/S0950-351X(88)
- van Rijn LE, Pop VJ, Williams GR. Low bone mineral density is related to high physiological levels of free thyroxine in peri-menopausal women. Eur J Endocrinol. 2014;170(3):461‐468. Published 2014 Feb 7. doi:10.1530/EJE-13-0769
- Yaylali O, Kirac S, Yilmaz M, et al. Does hypothyroidism affect gastrointestinal motility?. Gastroenterol Res Pract. 2009;2009:529802. doi:10.1155/2009/529802
- NHS “Erectile dysfunction (impotence)” 16 August 2017 https://www.nhs.uk/conditions/
- Kalra S, Unnikrishnan AG, Sahay R. The hypoglycemic side of hypothyroidism. Indian J Endocrinol Metab. 2014;18(1):1‐3. doi:10.4103/2230-8210.126517
- Abrams JJ, Grundy SM. Cholesterol metabolism in hypothyroidism and hyperthyroidism in man. J Lipid Res. 1981;22(2):323‐338.
- CJ Gardner, P Richardson, et al. Hypothyroidism in a patient with non-alcoholic fatty liver disease BMJ 2011; 342 doi: https://doi.org/10.1136/bmj.
- Sintzel F, Mallaret M, Bougerol T. Potentialisation par les hormones thyroïdiennes des traitements tricycliques et sérotoninergiques dans les dépressions résistantes [Potentializing of tricyclics and serotoninergics by thyroid hormones in resistant depressive disorders]. Encephale. 2004;30(3):267‐275. doi:10.1016/s0013-7006(04)
- Berent D, Zboralski K, Orzechowska A, Gałecki P. Thyroid hormones associated with depression severity and clinical outcome in patients with major depressive disorder. Mol Biol Rep. 2014;41(4):2419‐2425. doi:10.1007/s11033-014-3097-6
- Brănişteanu DE, Dimitriu A, Vieriu M, et al. Cutaneous manifestations associated with thyroid disease. Rev Med Chir Soc Med Nat Iasi. 2014;118(4):953‐958.
- B. Winsa, MD, A. Karlsson, MD et al. Stressful life events and Graves’ disease The Lancet VOLUME 338, ISSUE 8781, P1475-1479, DECEMBER 14, 1991 doi: https://doi.org/10.1016/0140-
- Matos‐Santos, A., Nobre, E.L., Costa, J.G.E., Nogueira, P.J., Macedo, A., Galvão‐Teles, A. and De Castro, J.J. (2001), Relationship between the number and impact of stressful life events and the onset of Graves’ disease and toxic nodular goitre★. Clinical Endocrinology, 55: 15-19. doi:10.1046/j.1365-2265.2001.
- Sategna-Guidetti C, Bruno M, Mazza E, et al. Autoimmune thyroid diseases and coeliac disease. Eur J Gastroenterol Hepatol. 1998;10(11):927‐931. doi:10.1097/00042737-
- Mainardi E, Montanelli A, Dotti M, Nano R, Moscato G. Thyroid-related autoantibodies and celiac disease: a role for a gluten-free diet?. J Clin Gastroenterol. 2002;35(3):245‐248. doi:10.1097/00004836-
- Roland Gärtner, Barbara C. H. Gasnier, Johannes W. Dietrich, Bjarne Krebs, Matthias W. A. Angstwurm, Selenium Supplementation in Patients with Autoimmune Thyroiditis Decreases Thyroid Peroxidase Antibodies Concentrations, The Journal of Clinical Endocrinology & Metabolism, Volume 87, Issue 4, 1 April 2002, Pages 1687–1691, https://doi.org/10.1210/jcem.
- Baeke F, Takiishi T, Korf H, Gysemans C, Mathieu C. Vitamin D: modulator of the immune system. Curr Opin Pharmacol. 2010;10(4):482‐496. doi:10.1016/j.coph.2010.04.001
- Arrieta MC, Bistritz L, Meddings JB. Alterations in intestinal permeability. Gut. 2006;55(10):1512‐1520. doi:10.1136/gut.2005.085373
- Langer P, Kocan A, Tajtaková M, et al. Fish from industrially polluted freshwater as the main source of organochlorinated pollutants and increased frequency of thyroid disorders and dysglycemia. Chemosphere. 2007;67(9):S379‐S385. doi:10.1016/j.chemosphere.
- Martin I. Surks, M.D., and Rubens Sievert, M.D. Drugs and Thyroid Function N Engl J Med 1995; 333:1688-1694 DOI: 10.1056/NEJM199512213332507
- Boukis MA, Koutras DA, Souvatzoglou A, Evangelopoulou A, Vrontakis M, Moulopoulos SD. Thyroid hormone and immunological studies in endemic goiter. J Clin Endocrinol Metab. 1983;57(4):859‐862. doi:10.1210/jcem-57-4-859
- Tomer Y, Huber A. The etiology of autoimmune thyroid disease: a story of genes and environment. J Autoimmun. 2009;32(3-4):231‐239. doi:10.1016/j.jaut.2009.02.007
- Vestergaard P, Rejnmark L, Weeke J, et al. Smoking as a risk factor for Graves’ disease, toxic nodular goiter, and autoimmune hypothyroidism. Thyroid. 2002;12(1):69‐75. doi:10.1089/105072502753451995
- Wajner SM, Goemann IM, Bueno AL, Larsen PR, Maia AL. IL-6 promotes nonthyroidal illness syndrome by blocking thyroxine activation while promoting thyroid hormone inactivation in human cells. J Clin Invest. 2011;121(5):1834‐1845. doi:10.1172/JCI44678
- Farhangi MA, Keshavarz SA, Eshraghian M, Ostadrahimi A, Saboor-Yaraghi AA. The effect of vitamin A supplementation on thyroid function in premenopausal women. J Am Coll Nutr. 2012;31(4):268‐274. doi:10.1080/07315724.2012.
- Hedrén E, Diaz V, Svanberg U. Estimation of carotenoid accessibility from carrots determined by an in vitro digestion method. Eur J Clin Nutr. 2002;56(5):425‐430. doi:10.1038/sj.ejcn.1601329
- Olivieri O, Girelli D, Stanzial AM, Rossi L, Bassi A, Corrocher R. Selenium, zinc, and thyroid hormones in healthy subjects: low T3/T4 ratio in the elderly is related to impaired selenium status. Biol Trace Elem Res. 1996;51(1):31‐41. doi:10.1007/BF02790145
- Drutel A, Archambeaud F, Caron P. Selenium and the thyroid gland: more good news for clinicians. Clin Endocrinol (Oxf). 2013;78(2):155‐164. doi:10.1111/cen.12066
- Zimmermann MB, Köhrle J. The impact of iron and selenium deficiencies on iodine and thyroid metabolism: biochemistry and relevance to public health. Thyroid. 2002;12(10):867‐878. doi:10.1089/105072502761016494
- Jain RB. Thyroid function and serum copper, selenium, and zinc in general U.S. population. Biol Trace Elem Res. 2014;159(1-3):87‐98. doi:10.1007/s12011-014-9992-9
- Abdel-Dayem, M.M., Elgendy, M.S. Effects of chronic estradiol treatment on the thyroid gland structure and function of ovariectomized rats. BMC Res Notes 2, 173 (2009). https://doi.org/10.1186/1756-
- Understanding Local Control of Thyroid Hormones: (Deiodinases Function and Activity) NAHIS https://www.nahypothyroidism.
- Nobuyuki Amino 4 Autoimmunity and hypothyroidism Baillière’s Clinical Endocrinology and Metabolism Volume 2, Issue 3, August 1988, Pages 591-617 doi: https://doi.org/10.1016/S0950-
- Yang, J., Yang, X. & Li, M. Baicalin, a natural compound, promotes regulatory T cell differentiation. BMC Complement Altern Med 12, 64 (2012). https://doi.org/10.1186/1472-
- Asvold BO, Bjøro T, Nilsen TI, Gunnell D, Vatten LJ. Thyrotropin levels and risk of fatal coronary heart disease: the HUNT study. Arch Intern Med. 2008;168(8):855‐860. doi:10.1001/archinte.168.8.855
- Anthony Martin Gerdes and Giorgio Iervasi Thyroid Replacement Therapy and Heart Failure Circulation 2010;122:385–393 https://doi.org/10.1161/
- Hiroaki Kimura and Patrizio Caturegli Chemokine Orchestration of Autoimmune Thyroiditis Thyroid 2007 17:10, 1005-1011 https://doi.org/10.1089/thy.
- Molnár I, Balázs C, Szegedi G, Sipka S. Inhibition of type 2,5′-deiodinase by tumor necrosis factor alpha, interleukin-6 and interferon gamma in human thyroid tissue. Immunol Lett. 2002;80(1):3‐7. doi:10.1016/s0165-2478(01)
- Kjellman BF, Ljunggren JG, Beck-Friis J, Wetterberg L. Reverse T3 levels in affective disorders. Psychiatry Res. 1983;10(1):1‐9. doi:10.1016/0165-1781(83)
- Mebis L, van den Berghe G. The hypothalamus-pituitary-thyroid axis in critical illness. Neth J Med. 2009;67(10):332‐340.
- Rannem T, Ladefoged K, Hylander E, Hegnhøj J, Staun M. Selenium depletion in patients with gastrointestinal diseases: are there any predictive factors?. Scand J Gastroenterol. 1998;33(10):1057‐1061. doi:10.1080/003655298750026750
- Vitamin B12 Health Sheet NIH March 30, 2020 https://ods.od.nih.gov/
- Schroeder AC, Privalsky ML. Thyroid hormones, t3 and t4, in the brain. Front Endocrinol (Lausanne). 2014;5:40. Published 2014 Mar 31. doi:10.3389/fendo.2014.00040
- Moncayo R, Kroiss A, Oberwinkler M, et al. The role of selenium, vitamin C, and zinc in benign thyroid diseases and of selenium in malignant thyroid diseases: Low selenium levels are found in subacute and silent thyroiditis and in papillary and follicular carcinoma. BMC Endocr Disord. 2008;8:2. Published 2008 Jan 25. doi:10.1186/1472-6823-8-2
- Guy E. Abraham, M.D. (1)and David Brownstein, M.D. Evidence that the administration of Vitamin C improves a defective cellular transport mechanism for iodine: A Case Report Optimox https://www.optimox.com/
- Anna J Duffield, Christine D Thomson, Kristina E Hill, Sheila Williams, An estimation of selenium requirements for New Zealanders, The American Journal of Clinical Nutrition, Volume 70, Issue 5, November 1999, Pages 896–903, https://doi.org/10.1093/ajcn/
- Hossein-nezhad A, Spira A, Holick MF. Influence of vitamin D status and vitamin D3 supplementation on genome wide expression of white blood cells: a randomized double-blind clinical trial. PLoS One. 2013;8(3):e58725. doi:10.1371/journal.pone.